Clinical trials: Baseline/Control Phase
Neurogenic Detrusor Overactivity
A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity
The purpose of this study was to investigate a medicine for the treatment of symptoms and complications of neurogenic detrusor overactivity (NDO) in children and adolescents.
- Trial name
- NCT01565694
- Testing
- Solifenacin succinate
- Where
- 21 sites in United States, Belgium and 8 more
- Volunteers
- 76 people
- Sponsor
- Astellas Pharma Europe B.V.
Neurogenic Detrusor Overactivity, Pediatric
A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)
The purpose of this study was to evaluate long term efficacy and safety of treatment with solifenacin succinate (the study drug) in children with neurogenic detrusor overactivity after multiple dose administration.
- Trial name
- NCT01981954
- Testing
- Solifenacin succinate
- Where
- 8 sites in United States, Belgium and 4 more
- Volunteers
- 23 people
- Sponsor
- Astellas Pharma Europe B.V.
Infertility
CONSORT Randomized Controlled Trial in Assisted Reproductive Technology
The overall objective of this trial is to compare the ovarian response in assisted reproductive technology (ART) subjects administered GONAL f® according to the 'Consistency in recombinant follicle stimulating hormone [r-FSH]…
- Trial name
- NCT00829244
- Testing
- GONAL f® prefilled pen
- Where
- Switzerland
- Volunteers
- 200 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Angiokeratomas
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)
The purpose of this study is to evaluate the safety and effectiveness of the experimental drug PTX-022 in the treatment of angiokeratomas
- Trial name
- LOTU (NCT07552077)
- Testing
- PTX-022
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Palvella Therapeutics, Inc.
Sickle Cell Disease
A Study of SHP655 (rADAMTS13) in Sickle Cell Disease
TAK-755 (previously known as SHP655) is a medicine used to treat sickle cell disease (SCD). The main aim of the study is to measure the safety and tolerability of TAK-755 in SCD participants.
- Trial name
- RAISE (NCT03997760)
- Testing
- TAK-755
- Where
- 14 sites in United States
- Volunteers
- 19 people
- Sponsor
- Shire
Relapsing Remitting Multiple Sclerosis
Safety, Tolerability And Mechanism Of Action Of Boswellic Acids (BA) In Multiple Sclerosis (SABA)
To determine the safety and tolerability of BOSWELAN in subjects with multiple sclerosis or clinically isolated syndrome and to describe the effect of Boswellic acids on the disease activity as assessed by monthly MRI measures.
- Trial name
- SABA (NCT01450124)
- Testing
- Boswellic acids (BOSWELAN)
- Where
- 2 sites in Germany
- Volunteers
- 29 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Stress Urinary Incontinence (SUI)
Evaluating SUI-100™, A Non-Invasive Device for the Treatment of Stress Urinary Incontinence
The goal of this pivotal clinical trial is to evaluate the safety and effectiveness of the SUI-100 device for the treatment of mild-to-moderate stress urinary incontinence (SUI) in females aged 22-70 years.
- Trial name
- SaHARA (NCT06862648)
- Testing
- Acoustic Stimulation Therapy Device
- Where
- 9 sites in United States
- Volunteers
- 130 people
- Sponsor
- Acoustic Wave Cell Therapy, Inc.
Neurogenic Detrusor Overactivity
Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity
The objective of the study was to evaluate the efficacy, safety, tolerability and pharmacokinetics of mirabegron after multiple-dose administration in the pediatric population.
- Trial name
- Crocodile (NCT02751931)
- Testing
- Mirabegron
- Where
- 32 sites in Australia, Belgium and 17 more
- Volunteers
- 91 people
- Sponsor
- Astellas Pharma Europe B.V.